EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Thionated levofloxacin derivative: Potential repurposing for cancer treatment and synergism with doxorubicin on doxorubicin-resistant lung cancer cells

Hamza Abumansour, Osama H Abusara iD, Mohammad Abu-Sini, Wiam Khalil, Ali I M Ibrahim, Amal M Badawoud, Majed S Al Yami iD, Dina H Abulebdah, Shiraz Halloush

PLOS One · 2025

DOI: 10.1371/journal.pone.0324930 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Hamza Abumansour und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan. Hauptthemen laut MEDLINE: Doxorubicin, Levofloxacin, Drug Resistance, Neoplasm, Drug Repositioning. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Al-Zaytoonah University of Jordan, Princess Nourah Bint Abdulrahman University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Fluoroquinolones, such as levofloxacin (LVX), are extended-spectrum drugs used for the treatment of bacterial infections. Several fluoroquinolone derivatives have shown promising antibacterial and anticancer activities. Our group has earlier synthesized and investigated thionated LVX analogs, compounds 2 and 3 , on A549 (non-small cell lung cancer) cell line and showed promising anticancer activity. The mechanism of cytotoxicity may be, in part, via aldehyde dehydrogenase enzyme inhibition and antioxidation. In this study, compounds 2 and 3 were evaluated on prostate (PC-3), breast (MCF7), colorectal (Caco-2), and small cell lung cancer (H69 and H69AR) cell lines.

Methods

The anticancer activity was measured using resazurin colorimetric method. Combination treatments with doxorubicin (DOX) were also employed and combination index (CI) value were calculated.

Results

Compound 3 possessed higher anticancer activity compared to compound 2 on the tested cancer cell lines. Compound 3 had the highest activity on PC-3 cells with IC 50 value of 3.58 µM. DOX was also tested for comparison and had IC 50 value of less than 0.5 µM in all tested cell lines except for H69AR (DOX-resistant form of H69), which was 4.62 µM. Combination treatment with DOX resulted in significant reduction of cell viability in PC-3, H69, and H69AR cells, with those on H69 and H69AR cells resulted in additive (CI = 1.0) and synergistic effects (CI = 0.6), respectively.

Conclusions

Compound 3 , a thionated LVX derivative, showed a promising anticancer activity, prompting its potential repurposing for cancer treatment as well as combination treatment with DOX on DOX-resistant cancer cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinLevofloxacinDrug Resistance, NeoplasmDrug RepositioningLung NeoplasmsAntineoplastic AgentsHumansDrug SynergismCell Line, TumorCell Survival

Substanzen

DoxorubicinLevofloxacinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.
  • Department of Pharmacology, School of Medicine, The University of Jordan, Amman, Jordan.
  • Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
  • King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia.
  • King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.

ORCID-Profile: Osama H Abusara, Majed S Al Yami

Förderung

  • Al-Zaytoonah University of Jordan
  • Princess Nourah Bint Abdulrahman University

Zitieren

APA

Abumansour, H., Abusara, O. H., Abu-Sini, M., Khalil, W., Ibrahim, A. I. M., Badawoud, A. M., Al Yami, M. S., Abulebdah, D. H., & Halloush, S. (2025). Thionated levofloxacin derivative: Potential repurposing for cancer treatment and synergism with doxorubicin on doxorubicin-resistant lung cancer cells. PLOS One. https://doi.org/10.1371/journal.pone.0324930

Vancouver

Abumansour H, Abusara OH, Abu-Sini M, Khalil W, Ibrahim AIM, Badawoud AM, et al. Thionated levofloxacin derivative: Potential repurposing for cancer treatment and synergism with doxorubicin on doxorubicin-resistant lung cancer cells. PLOS One. 2025. doi:10.1371/journal.pone.0324930

BibTeX
@article{Abumansour2025,
  author = {Abumansour, Hamza and Abusara, Osama H and Abu-Sini, Mohammad and Khalil, Wiam and Ibrahim, Ali I M and Badawoud, Amal M and Al Yami, Majed S and Abulebdah, Dina H and Halloush, Shiraz},
  title = {Thionated levofloxacin derivative: Potential repurposing for cancer treatment and synergism with doxorubicin on doxorubicin-resistant lung cancer cells},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0324930}
}
Kostenlos starten →